Showing 312 results
May 2022
-
Media ReleaseSandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders Action Plan will provide…
-
Media ReleaseSandoz appoints new Board representative to global AMR Industry AllianceDr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA) The Alliance brings together about 100 life…
-
Media ReleaseSandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolioPirfenidone is used to treat idiopathic pulmonary fibrosis (IPF),1 a progressive disease that causes irreversible lung scarring and makes it difficult to breathe2 Approximately 140,000 Americans…
April 2022
-
Media ReleaseNovartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlookAd hoc announcement pursuant to Art. 53 LR Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD) Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core operating…
-
Media ReleaseSandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolioBrimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1 Ocular hypertension affects over 5% of all adults2; the eye does…
-
Media ReleaseSandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025 Both parties strengthening…
February 2022
-
Media ReleaseSandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicineLenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4 Cost savings from Lenalidomide Sandoz can expand treatment options for …
-
Media ReleaseNovartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021Ad hoc announcement pursuant to Art. 53 LR Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD) IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +…
December 2021
-
Media ReleaseSandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMASubmission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc. Breast cancer is one of most common types…
-
Media ReleaseSandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDABiologics License Application (BLA) is supported by analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc. Trastuzumab is monoclonal antibody used to…